[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL1987038T3 - Inhibitory HCV NS5B - Google Patents

Inhibitory HCV NS5B

Info

Publication number
PL1987038T3
PL1987038T3 PL07763294T PL07763294T PL1987038T3 PL 1987038 T3 PL1987038 T3 PL 1987038T3 PL 07763294 T PL07763294 T PL 07763294T PL 07763294 T PL07763294 T PL 07763294T PL 1987038 T3 PL1987038 T3 PL 1987038T3
Authority
PL
Poland
Prior art keywords
hcv ns5b
ns5b inhibitors
compounds
hcv
inhibitors
Prior art date
Application number
PL07763294T
Other languages
English (en)
Inventor
Carl P Bergstrom
Scott W Martin
Thomas W Hudyma
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PL1987038T3 publication Critical patent/PL1987038T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
PL07763294T 2006-02-08 2007-02-07 Inhibitory HCV NS5B PL1987038T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77139106P 2006-02-08 2006-02-08
EP07763294A EP1987038B1 (en) 2006-02-08 2007-02-07 Hcv ns5b inhibitors
PCT/US2007/061768 WO2007092888A2 (en) 2006-02-08 2007-02-07 Hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
PL1987038T3 true PL1987038T3 (pl) 2011-03-31

Family

ID=38234480

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07763294T PL1987038T3 (pl) 2006-02-08 2007-02-07 Inhibitory HCV NS5B

Country Status (17)

Country Link
US (1) US7456165B2 (pl)
EP (1) EP1987038B1 (pl)
JP (1) JP5147731B2 (pl)
KR (1) KR20080102161A (pl)
CN (1) CN101379066B (pl)
AT (1) ATE483712T1 (pl)
AU (1) AU2007211988B2 (pl)
CY (1) CY1111423T1 (pl)
DE (1) DE602007009646D1 (pl)
DK (1) DK1987038T3 (pl)
ES (1) ES2352574T3 (pl)
HR (1) HRP20100672T1 (pl)
NO (1) NO20083513L (pl)
PL (1) PL1987038T3 (pl)
PT (1) PT1987038E (pl)
SI (1) SI1987038T1 (pl)
WO (1) WO2007092888A2 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005049622A1 (ja) * 2003-11-19 2007-06-07 日本たばこ産業株式会社 ５−５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) * 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
AU2008338273B2 (en) 2007-12-19 2014-10-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2009120733A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
MX2010010245A (es) * 2008-03-27 2010-10-05 Bristol Myers Squibb Co Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona.
ES2374870T3 (es) 2008-03-27 2012-02-22 Bristol-Myers Squibb Company Inhibidores de ns5b de vhc de indolobenzadiazepina fusionada con heterocíclicos aromáticos.
KR20100139082A (ko) * 2008-03-27 2010-12-31 브리스톨-마이어스 스큅 컴퍼니 Ｃ형 간염 치료를 위한 화합물
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
EP2396329B1 (en) * 2009-02-11 2014-10-29 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
JP5918264B2 (ja) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
BR112013016480A2 (pt) 2010-12-30 2016-09-20 Abbvie Inc macrocíclo da fenantridina inibadores da protease da serina da hepatite c
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN102276531A (zh) * 2011-05-30 2011-12-14 扬子江药业集团广州海瑞药业有限公司 一种甲磺酸非诺多泮的制备方法
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CN104447952A (zh) * 2014-12-11 2015-03-25 上海唐润医药科技有限公司 丙肝病毒蛋白酶抑制剂及其合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138109A1 (en) * 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
CN100453553C (zh) * 2003-04-11 2009-01-21 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
PL1719773T3 (pl) 2004-02-24 2009-08-31 Japan Tobacco Inc Skondensowane związki heterotetracykliczne i ich zastosowanie jako inhibitora polimerazy HCV
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
ATE384723T1 (de) 2004-10-13 2008-02-15 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
KR20070068427A (ko) 2004-10-26 2007-06-29 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. 항바이러스제로서의 테트라사이클릭 인돌 유도체
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors

Also Published As

Publication number Publication date
KR20080102161A (ko) 2008-11-24
ATE483712T1 (de) 2010-10-15
DE602007009646D1 (de) 2010-11-18
EP1987038B1 (en) 2010-10-06
PT1987038E (pt) 2010-12-09
AU2007211988B2 (en) 2012-02-02
WO2007092888A2 (en) 2007-08-16
ES2352574T3 (es) 2011-02-21
JP5147731B2 (ja) 2013-02-20
NO20083513L (no) 2008-10-14
CY1111423T1 (el) 2015-08-05
US7456165B2 (en) 2008-11-25
CN101379066A (zh) 2009-03-04
DK1987038T3 (da) 2011-01-31
EP1987038A2 (en) 2008-11-05
CN101379066B (zh) 2011-08-03
WO2007092888A3 (en) 2007-10-11
HRP20100672T1 (hr) 2011-01-31
SI1987038T1 (sl) 2011-02-28
JP2009526081A (ja) 2009-07-16
AU2007211988A1 (en) 2007-08-16
US20070185083A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
PL1987038T3 (pl) Inhibitory HCV NS5B
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
MX2009004943A (es) Inhibidores del virus de la hepatitis c.
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
MY142240A (en) Hcv ns3 protease inhibitors
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
UA90909C2 (en) Hcv ns3 protease inhibitors
MX2010010235A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.
UA95990C2 (en) Hcv ns3 protease inhibitors
MX2010010060A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados, heterociclicos y aromaticos.
TW200614989A (en) Inhibitors of HCV replication